The global cancer biomarkers market size is expected to reach around US$ 32.09 billion by 2030 from US$ 10.69 billion in 2021 and is expected to grow at an impressive double-digit rate of 13% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global cancer biomarkers market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Report Highlights
- On the basis of type, breast cancer segment holds the largest market share in the global cancer biomarkers market. The growing prevalence of breast cancer among working women is driving the segment growth over the projected period.
- On the basis of biomolecule, genetic biomarkers segment holds the largest market share in the global cancer biomarkers market. The genetic biomarkers are widely employed for the treatment of cancer.
- On the basis of application, diagnostics segment holds the largest market share in the global cancer biomarkers market. During the projected period, the factors such as the expanding development of cancer biomarkers based on oncology tests with high efficiency are driving the segment growth.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1637
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global cancer biomarkers market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global cancer biomarkers market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Market Dynamics
Drivers
Growing incidences of cancer
The cases of cancer disease are growing at a rapid pace. The biomarkers are used predominantly for the treatment of cancer. As per statistics provided by World Cancer Research Fund International, in 2018 around 18 million people were suffering from cancer. Moreover, lung cancer and breast cancer are life threatening cancers. As a result, growing incidences of cancer is driving the growth of the global cancer biomarkers market during the forecast period.
Restraints
Lack of reimbursement policies
The government in underdeveloped and developing countries does not provide favorable reimbursement policies. The need for reimbursement policies is growing due to surge in the number of cancer patients. In addition, these nations lack for proper resources for the development of cancer biomarkers. The financial conditions are not favorable in these regions. The developed countries’ government help these countries to develop novel products. In addition, they also fund healthcare sector in these regions. Thus, lack of reimbursement policies is restricting the growth of the global cancer biomarkers market.
Opportunities
Growing technological developments
The technological advancements are helping to develop cancer biomarkers with advanced features. The innovation in technologies is also assisting in finding new ways to ways for dealing with cancer diseases. The latest technologies are addressing new problems that healthcare sector is facing since few years. With the help of innovative technologies, new devices and gadgets are being developed and manufactured that help in the treatment of cancer. Thus, growing technological developments is creating lucrative opportunities for the growth of the global cancer biomarkers market over the forecast period.
Challenges
High cost for treatment and diagnosis
The developing and underdeveloped countries cannot afford for the treatment and diagnosis of cancer. The treatment is very costly as devices used for the cancer treatment are deployed with latest and advanced technologies. This factor adds up to the final cost of treatment and diagnosis. As a result, high cost of treatment and diagnosis is a major challenge for the expansion of the global cancer biomarkers market.
Recent Developments
- Agilent Technologies Inc. announced the commencement of the Biomarker Pathologist Training Program in November 2020, which is a global project designed to help pathologists evaluate biomarkers accurately. Formerly, the program was only offered in Europe and North America.
- Oncotype DX Ar-V7 nucleus detect test was introduced by Genomic Healthcare Inc., in March 2018. The AR-V7 protein is a biomarker that can be used to predict and diagnose cancer.
- Roche announced in March 2021 that the VENTANA ALK CDx Assay had been approved as a companion diagnostic by the FDA.
Why should you invest in this report?
If you are aiming to enter the global cancer biomarkers market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cancer biomarkers are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global cancer biomarkers market include:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- Abbott Laboratories
- Exact Sciences
- Meso Scale Diagnostics LLC
- Seegene Technologies Inc.
- Siemens Healthineers
Market Segmentation:
By Type
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Others
By Biomolecule
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Others
By Application
- Drug Discovery and Development
- Diagnostics
- Personalized Medicine
- Others
By Profiling Technology
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics-based Tests
By End User
- Hospitals
- Academic and Cancer Research Institutes
- Ambulatory Surgical Centres
- Diagnostic Laboratories
Regional Analysis:
The geographical analysis of the global cancer biomarkers market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global cancer biomarkers Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global cancer biomarkers market in 2030?
- What is the expected CAGR for the cancer biomarkers market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global cancer biomarkers market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Biomarkers Market
5.1. COVID-19 Landscape: Cancer Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Biomarkers Market, By Type
8.1. Cancer Biomarkers Market, by Type, 2022-2030
8.1.1. Breast Cancer
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Prostate Cancer
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Cervical Cancer
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Liver Cancer
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Lung Cancer
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cancer Biomarkers Market, By Biomolecule Type
9.1. Cancer Biomarkers Market, by Biomolecule Type, 2022-2030
9.1.1. Genetic Biomarkers
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Epigenetic Biomarkers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Metabolic Biomarkers
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Proteomic Biomarkers
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cancer Biomarkers Market, By Application Type
10.1. Cancer Biomarkers Market, by Application Type, 2022-2030
10.1.1. Drug Discovery and Development
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diagnostics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Personalized Medicine
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cancer Biomarkers Market, By Profiling Technology
11.1. Cancer Biomarkers Market, by Profiling Technology Type, 2022-2030
11.1.1. Omic Technologies
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Imaging Technologies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Immunoassays
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Cytogenetics-based Tests
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Cancer Biomarkers Market, By End User Type
12.1. Cancer Biomarkers Market, by End User, 2022-2030
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Academic and Cancer Research Institutes
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Ambulatory Surgical Centres
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Diagnostic Laboratories
12.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Cancer Biomarkers Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2017-2030)
13.1.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.1.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.1.5. Market Revenue and Forecast, by End User (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.1.7. Market Revenue and Forecast, by End User (2017-2030)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.1.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.1.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.1.8.5. Market Revenue and Forecast, by End User (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.2.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.2.5. Market Revenue and Forecast, by End User (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.7. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.2.8. Market Revenue and Forecast, by End User (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.10. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.2.11. Market Revenue and Forecast, by End User (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.2.13. Market Revenue and Forecast, by End User (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.2.15. Market Revenue and Forecast, by End User (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.3.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.3.5. Market Revenue and Forecast, by End User (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.3.7. Market Revenue and Forecast, by End User (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.3.9. Market Revenue and Forecast, by End User (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.3.10.5. Market Revenue and Forecast, by End User (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.3.11.5. Market Revenue and Forecast, by End User (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.4.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.4.5. Market Revenue and Forecast, by End User (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.4.7. Market Revenue and Forecast, by End User (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.4.9. Market Revenue and Forecast, by End User (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.4.10.5. Market Revenue and Forecast, by End User (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.4.11.5. Market Revenue and Forecast, by End User (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2017-2030)
13.5.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.5.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.5.5. Market Revenue and Forecast, by End User (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.5.7. Market Revenue and Forecast, by End User (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)
13.5.8.5. Market Revenue and Forecast, by End User (2017-2030)
Chapter 14. Company Profiles
14.1. F. Hoffmann-La Roche Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Thermo Fisher Scientific Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. QIAGEN N.V.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Illumina Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bio-Rad Laboratories Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Abbott Laboratories
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Exact Sciences
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Meso Scale Diagnostics LLC
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Seegene Technologies Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Siemens Healthineers
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1637
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments